Home › Gilead Announces Interim Phase 2 Results for GS-9973 in Previously...
 

Keywords :   


Gilead Announces Interim Phase 2 Results for GS-9973 in Previously...

2013-12-08 05:39:25| Biotech - Topix.net

Gilead Sciences, Inc. today announced interim results from a single-arm, open-label Phase 2 study evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase , for the treatment of patients with relapsed or refractory hematologic malignancies.

Tags: in results previously phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.11Tropical Storm Sara Graphics
15.11Tropical Storm Sara Forecast Discussion Number 8
15.11Tropical Storm Sara Wind Speed Probabilities Number 8
15.11Tropical Storm Sara Public Advisory Number 8
15.11 20213 105S P7905-P
15.11 ()
15.11Mizuno Energy 25.5
15.11
More »